

APASL STC 2025 Tokyo

Poster Session Program Day 1 (Thursday October 2)

Session #	Date	Time	Session Topics	No.	First Name	Last Name	Country/District	Title of Abstract
1	10/2 (Thr)	17:40 - 18:10	Late-Breaking	10236	Kaye Bernice T.	Siao	Philippines	Drug Induced Liver Injury Secondary to Anabolic Steroid Use in a Young Filipino Male: A Case Report and Therapeutic Challenge
				10237	Fahmi Fauzi	Sugandi	Indonesia	Acute Liver Failure Due to Anti-Tuberculosis Drug-Induced Liver Injury: A Case Report from Indonesia
				10238	Kenji	Takemoto	USA	Zonal Differences in Hepatocellular Mitochondrial Depolarization, Mitophagy, and Respiration after Acute Ethanol
				10240	Matthew	Bryant	USA	ONCE-MONTHLY EFIMOSFERMIN ALFA (BOS-580) IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS WITH F2/F3 FIBROSIS: RESULTS FROM A 24 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL
				10244	Taishi	Hashiguchi	Japan	Therapeutic evaluation of resmetirom and semaglutide in the STAM mouse model: bridging surrogate and clinical outcomes
2	10/2 (Thr)	18:10 - 18:40	Other Liver Disease-Clinical/ Other Liver Disease-Experimental	10154	Eduward	Thendiono	Indonesia	The Impact of Branch-Chained Amino Acid plus Ringer's Acetate Infusion in the Management of Dengue-Related Hepatitis
				10194	Ga-Young	Kim	Korea	Understanding of the Involvement of Cxcl1-associated Neutrophil Infiltration in APAP-Induced Liver Injury
				10191	Wenkang	Gao	China	Escherichia Coli Expressing the kpsM Gene Exacerbates Drug-induced Liver Injury
				10105	Oyunjargal	Baterdene	Japan	Elucidating the Role of Ferroptosis in Acute Liver Injury Models
				10208	Rimsha	N. A.	Pakistan	Plastic Diets and Liver Dilemmas: Uncovering the Hepatotoxic Divide between Synthetic and Bioplastics
3	10/2 (Thr)	17:40 - 18:10	MASLD-Experimental	10064	Sunita	Giri	India	Enhanced Expression of the FTO Gene in the Liver Correlates with the Progression of Metabolic Dysfunction Associated Steatotic Liver Disease
				10116	Charupong	Saengboonmee	Thailand	Using Non-nutritive Sweeteners in a Fasting Period did not Disturb the Metabolic Benefits and Might Improve Gut Microbiota in Obese Mice Practicing Intermittent Fasting
				10103	Humaira	Shahai	Malaysia	Non Alcoholic Fatty Liver Disease NAFLD: The Estrogen Gut Liver Axis and the Emerging Role of Endometriosis
				10233	Satoshi	Sakuma	Japan	Metabolic Dysfunction-associated Steatohepatitis Exacerbates LPS-induced Liver Injury and Mortality in Obese KK-Ay Mice
				10145	Akira	Sakamaki	Japan	Oral Ethanol Administration Induces Hepatitis in Mice with Combining Maternal Id-like Molecule and Melanocortin-4 Receptor Gene Deletions
4	10/2 (Thr)	18:10 - 18:40	MASLD-Clinical	10232	Hiroo	Fukada	Japan	Impact of Dapagliflozin on Liver Function and Body Composition in MASLD with T2DM: A Randomized Controlled Trial
				10001	Veronika	Gomonova	Russia	Validation of CASLI, Fibroscan-AST (FAST), and Agile3+ in a Russian Cohort of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease
				10005	Xinhe	Zhang	China	Identification of Biomarkers for Progression from NAFL to NASH by Bioinformatics and Mendelian Randomization
				10018	Tomohide	Kurahashi	Japan	Impact of SGLT2 Inhibitors on Liver Imaging Screening and Fibrosis in Diabetes Patients with MASLD
				10024	Tomohide	Kurahashi	Japan	Efficacy of Imeglimin Hydrochloride in Diabetic Steatotic Liver Disease: A Retrospective Analysis
5	10/2 (Thr)	17:40 - 18:10	ALD-Clinical/ ALD-Experimental	10047	Junichi	Hanatani	Japan	Efficacy and Safety of Nalmefene in Alcohol-Related Liver Disease
				10164	Yasuka	Eriksson	Japan	A Retrospective Study on the Prognosis of Patients with Alcoholic Liver Cirrhosis
				10173	Mirudhula	Gnanavelou	Singapore	Outcomes of Alcoholic Liver Disease in Liver Transplantation: A Systematic Review and Meta-analysis
				10097	Hideki	Fujii	Japan	How Sex and Age Modify the Influence of BMI, CMRFs, and Alcohol on SLD Diagnosis
				10245	Tian Jiao	Chen	China	Drinking patterns and the risk of alcoholic liver disease
6	10/2 (Thr)	18:10 - 18:40	ALD-Experimental/ Fibrosis-Experimental/ MASLD-Clinical	10020	Yoshino	Sakuma	Japan	Novel Serum Marker Proteins for Alcohol Abuse Identified through Proteomic Analysis
				10150	Hien T. T.	L.	Viet Nam	Comparative Liver Fibrosis Severity in Alcohol-Related Liver Disease and Chronic Viral Hepatitis Using Transient Elastography
				10200	Satoko	Tajirika	Japan	Skeletal Muscle Loss and Elevated Phase Angle are Linked to Metabolic Dysfunction-associated Steatotic Liver Disease in Japanese Males
				10214	Peter Chen-Yang Nikhil	Daniel	Singapore	A 50% Relative Decline in MRI-PDFF Predicts Fibrosis Improvement in Metabolic Dysfunction-associated Steatohepatitis
				10217	Narina	Sargsyants	Armenia	Role of Coffee Consumption among Patients with Steatotic Liver Diseases in Armenia
7	10/2 (Thr)	17:40 - 18:10	MASLD-Clinical	10218	Han Ah	Lee	Korea	Risk of Liver-Related Events in MASLD: Impact of cardiometabolic Risk Factor Count and Its Longitudinal Changes
				10224	Fardah	Akil	Indonesia	The Interplay of Hepatic Steatosis and Fibrosis in MASLD: Insights from a Clinical Scoring Approach
				10212	Andi	Nursanti	Indonesia	Halalopathy in Metabolic Dysfunction-Related Steatotic Liver Disease/MASLD Management: A Holistic Approach to Enhancing Quality of Life for Muslim Patients
				10066	Eun Seok	Kang	Korea	Liver-related Event Risk in Steatotic Liver Disease According to Smoking Transitions and Subsequent Use of Nicotine Alternatives
				10067	Katsuya	Nagaoka	Japan	Elevated M2BPGi is Associated with Increased White Matter Hyperintensities, Cognitive Impairment, and Slower Gait Speed in Older Adults with MASLD
8	10/2 (Thr)	18:10 - 18:40	ALD-Experimental/ MASLD-Clinical/	10015	Kosuke	Kaji	Japan	Elafibranor Ameliorates Liver Fibrosis Development and Repairs Gut Barrier Function in a Mouse Alcohol-associated Liver Disease Model
				10060	Dharmendra K.	Khatri	India	Hepatoprotective Potential of Phloretin in Alcohol-Induced Liver Disease (ALD) Rat Model: Biochemical and Molecular Evidence
				10179	Joo-Hyun	Park	Korea	Association between Metabolic Dysfunction-associated Steatotic Liver Disease and Young-onset Thyroid Cancer Risk in Men and Women: A Nationwide Cohort Study of Adults Aged 20-39 Years
				10190	Naryasu	Kakita	Japan	Serum Zinc Deficiency Reflects Nutritional Impairment Rather Than Fibrosis Severity in MASLD: A Biopsy-Based Study of 193 Cases
				10140	Taek-Kyong	Kim	Korea	Unraveling the Role of Hepatocyte-Specific DDIT4 in Alcohol-Induced Hepatic Injury
9	10/2 (Thr)	17:40 - 18:10	ALD-Clinical/ Liver Fibrosis-Experimental/ Liver Tumor-Clinical/ MASLD-Clinical	10210	Jumriani	Jumriani	Indonesia	Culture vs Health: How Traditional Drink Tuak Be a Risk Factor Enhance Liver Disease?
				10023	Masayoshi	Takami	Japan	Involvement of the ADAMTS13/von Willebrand Factor Axis in Acute Kidney Injury in Mice with Advanced Fibrotic Liver
				10092	Yoshie	Kadota	Japan	A Case of Esophago-Tracheal Fistula during Atezolizumab plus Bevacizumab after Endoscopic Submucosal Dissection of the Esophagus
				10109	Yutaka	Yata	Japan	Dynamic Status of Metabolic Syndrome and Hepatocellular Carcinogenesis: A Big Data Analysis from Japan
				10072	Jong-Ho	Park	Korea	Predictive Utility of Polygenic Risk Scores for Metabolic Dysfunction-Associated Fatty Liver Disease
10	10/2 (Thr)	18:10 - 18:40	MASLD-Clinical	10038	Yijing	Wu	China	Effects of Probiotics on Gut Microbiota in Patients with Type 2 Diabetes
				10046	Dae Won	Jun	Korea	Misclassification of Alcohol Use Disorder in MASLD and MetALD: Prevalence, Clinical Characteristics, and Outcomes
				10093	Nurgul	Toktogulova	Kyrgyz	Features of the Course of Metabolically Associated Fatty Liver Disease in Lean Elderly Residents of mid-altitude Areas
				10114	Atteyat A.	Semeya	Egypt	Screening for Metabolic-associated Fatty Liver Disease in Type 2 Diabetes Patients Using Non-invasive Scores and Ultrasound: a Cross-sectional Study in Egypt
				10229	Narina	Sargsyants	Armenia	Noninvasive NASH-FibroTest in Armenian Patients with Steatotic Liver
11	10/2 (Thr)	17:40 - 18:10	Fibrosis-Experimental	10026	Weicheng	Liang	China	Aging Increased the Susceptibility of Liver Fibrosis through Enhancing NAT10-mediated ac4C Modification of TGF beta1 mRNA
				10082	Yi-Jen	Liao	Taiwan	Dietary Fermented Rice Bran Inhibit Liver Fibrosis and Hepatic Stellate Cells Activation in Mice
				10183	Steven L.	Xius	Indonesia	A Bioinformatics Dissection of TGF-β Signaling in Human Hepatic Stellate Cells: Uncovering Novel Fibrogenic Genes
				10196	Kirara	Inoue	Japan	Characterization of Hepatocyte Plasma Membrane Proteins that Regulate Hepatic Stellate Cell Activation
				10235	Xingchen	Liu	Japan	Fibroblast Growth Factor (FGF) 18 Promotes Proliferation and Migration of Murine Hepatic Stellate Cells
12	10/2 (Thr)	18:10 - 18:40	MASLD-Clinical/ Other Liver Disease-Clinical	10028	Mary Yue	Wang	Hong Kong	Optimal Hemoglobin A1c (HbA1c) Target for Preventing Liver-related Complications in Individuals with Type 2 Diabetes Mellitus (T2DM) with and without Cirrhosis: A Territory-wide Retrospective Cohort Study from 2000 to 2023
				10099	Walced Attia	Hassan	Egypt	Liver Stiffness Measurement, Doppler Ultrasound, and Serum Non-Invasive Markers as Predictors of Varices and Variceal Bleeding in Cirrhotic Patients
				10209	Ayush	Jasrotia	India	Hemobilia Due to Spontaneous Arterioportal Fistula in a Liver Abscess: A Rare Case Report
				10034	Amar	Ranjan	India	Analysis of Lesions of Liver in Postmortem Cases in Indian Population
				10211	Jumriani	Jumriani	Indonesia	Traditional Use of Gabus Fish by the Mandar People: Relevance to Liver Health and Post Surgical Healing
13	10/2 (Thr)	17:40 - 18:10	Liver Transplantation-Clinical/ Public Health/ Viral Hepatitis-Clinical	10166	Wen Hui	Lim	Singapore	Predicting Spontaneous Clinical Recompensation in Liver Transplant Candidates: A Competing Risks Analysis of the UNOS Registry
				10202	Ranbir	Singh	India	Impact of Deep Breathing, Laughter Yoga, and Clapping Exercises on Hypoglycemia and Quality of Life in Post-Liver Transplantation Patients in Central Delhi
				10068	Shuntaro	Obi	Japan	Regional Differences in HCC Etiology: Interim Report from the A-HOC Consortium
				10077	Tomoko	Tanaka	Japan	Temporal Relationship between Hepatocarcinogenesis after Sustained Virologic Response and Insulin Resistance in Patients with Chronic Hepatitis C
				10180	Nami	Mori	Japan	Lenvatinib Plus TACE for HCC: A Comparison of the Protocols and the Clinical Utility of Lenvatinib Continuation
14	10/2 (Thr)	18:10 - 18:40	Liver Tumor-Clinical	10185	Takashi	Nishimura	Japan	Therapeutic Sequences of Systemic Therapy after Atezolizumab plus Bevasizumab Based on BR-HCC Expert Consensus 2023
				10188	Naruyasu	Kakita	Japan	Mass-forming Eosinophilic Hepatitis Mimicking Recurrent Hepatocellular Carcinoma after Surgical Resection: A Case Report
				10118	T.	Motomura	Japan	Impact of PNPLA3 Genetic Variant on NBNC-HCC Recurrence
				10158	Toan Bao	Nguyen	Viet Nam	Evaluation of the Diagnostic Performance of the GAAD Score with a 2.57 Cutoff for Hepatocellular Carcinoma in Vietnamese Patients
				10055	Monirujjaman	Biswas	India	Metastatic Liver Tumors: A Retrospective Spectrum of Differential Diagnoses from a North Indian Tertiary Health Center
15	10/2 (Thr)	17:40 - 18:10	Liver Tumor-Clinical	10096	Jobel Feliz C	Castillo	Philippines	Imaging-Pathology Discordance in a Rare Case of Mucinous Intrahepatic Cholangiocarcinoma Presenting as a Cystic Liver Lesion
				10054	Monirujjaman	Biswas	India	Clinicopathological Insights into Pediatric Liver Tumors: A North Indian Tertiary Hospital Setting
				10131	Mohamed	Abdel-Samiee	Egypt	XRCC1 Gene Polymorphism and the Risk of Hepatocellular Carcinoma in Egypt
				10089	Amany	Rashad	Egypt	Hepatocyte Nuclear Factor 1 Alpha Variants as a Risk Factor for Hepatocellular Carcinoma Development with/without Diabetes Mellitus
				10004	Tadashi	Namisaki	Japan	Histological Stage as Predictor of the Complications of Primary Biliary Cholangitis
16	10/2 (Thr)	18:10 - 18:40	Other Liver Disease-Clinical/ Other Liver Disease-Experimental	10215	Nazugum A.	Ashimova	Kazakhstan	The Role of Non-Invasive Methods and Serological Biomarkers in the Diagnosis and Morphological Characterization of Autoimmune Hepatitis with Correlation to Liver Biopsy Findings
				10030	Ngan Thanh Quynh	Le	Viet Nam	Drug- induced Autoimmune Hepatitis
				10184	Lim	Kai	Singapore	The Liver That Looked Malignant: Autoimmune Hepatitis Masquerading as Malignancy-A case for Clinical Judgment in Hepatology
				10120	Erdenetsogt	Dungubat	Japan	Inhibitory Effects of Haskap Fruit Extract on Animal Models of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
				10056	Balzhan	Abzhaparova	Kazakhstan	Prevalence and Genotypes Distribution of Virus Hepatitis B and Hepatitis Delta Virus in Chronic Liver Diseases in Kazakhstan
17	10/2 (Thr)	17:40 - 18:10	Viral Hepatitis-Clinical	10069	Shuntaro	Obi	Japan	Fat Accumulation as a Risk Factor for HCC and Extrahepatic Cancers After SVR: A Prospective Study Based on Fibro Scan Derived Stratification
				10070	Shuntaro	Obi	Japan	Post-SVR Dynamics of Hepatic Steatosis: Divergent Patterns by Fibrosis Stage and Implications for HCC Risk
				10138	Hien T. T.	L.	Viet Nam	Evaluation of Shortened DAA Regimens (Sofosbuvir + Velpatasvir, Sofosbuvir + Daclatasvir) in Chronic Hepatitis C Patients Based on Early Virological Response
				10204	Tomiko	Koyama	Japan	Evaluation of HCV Duo as a Primary Tool for Hepatitis C Screening in Japan

APASL STC 2025 Tokyo

Poster Session Program Day 2 (Friday October 3)

Session #	Date	Time	Session Topics	No.	First Name	Last Name	Country/District	Title of Abstract
18	10/3 (Fri)	13:00-13:30	Liver Tumor-Experimental/ Public Health	10189	Misako	Sato-Matsubara	Japan	PARPBP as a Prognostic Biomarker Linked to Tumor Differentiation and Immune Microenvironment in Hepatocellular Carcinoma
				10083	Ming-Syuan	Shih	Taiwan	ANGPTL6 Regulates Epithelial Mesenchymal Transition in Liver Cancer
				10107	Takako	Inoue	Japan	The Effectiveness of Hepatitis Medical Care Coordinator Certification among Dentists: Seven Years of Progress by the Aichi Dental Association
				10168	Fatimah Bt	Abd Kadir	Malaysia	Photocatalytic Degradation of Methylene Blue to Mitigate Liver Disease: A Step Toward Sustainable Wastewater Treatment
				10123	Nahya	Nur	Indonesia	Comparison of Machine Learning Algorithm in Predicting Living Status of Hepatitis Patients
19	10/3 (Fri)	13:30-14:00	Liver Tumor-Experimental/ Other Liver Disease-Experimental/ Public Health	10198	Sohji	Nishina	Japan	Photothermally Modulated Liposome Enabling Efficient Release of Glucose Analogue Safely Displays Vigorous Antitumor Effect against Liver Cancer
				10088	Tatsuo	Kanda	Japan	Inhibition of HAV Replication by Azathioprine in Vitro
				10101	Shah	Shahik	Bangladesh	Novel Multi-Epitope Subunit Vaccine for Hepatitis Viruses: An Immunoinformatic Approach
				10037	Xinyue	Wang	China	Influence of Gut Microbiota on the Gut-Brain Axis and Neurological Disorders
				10086	Nisrin bt	Abd Kadir	Malaysia	Rice Contamination and Liver Disease Risk: A Study on Pesticide Effects on Rice Nutritional Quality
20	10/3 (Fri)	13:00-13:30	Liver Transplantation-Clinical/ Liver Transplantation-Experimental/ Viral Hepatitis-Clinical	10002	Ulil Albab	Habibah	Indonesia	Comparison of Effectiveness of Mycophenolate Mofetil Associated with Standard Dose or Low Dose Tacrolimus for Liver Transplantation Immunosuppression
				10234	Muhammad Zakria	Wahla	Pakistan	Assessment of Segment 5 and Segment 8 Congestion In Right Lobe Liver Graft
				10061	Parag K	Rane	India	Liver-Targeted Nanoparticle Delivery of Tacrolimus Enhances Immunosuppression and Minimizes Systemic Toxicity in a Rat Liver Transplant Model
				10090	Abdelghani	Badran	Egypt	Role of Fibroscan in the Early Detection of Hepatocellular Carcinoma in 1000 Cirrhotic Egyptian Patients
				10127	Mohamed	Abdel-Samiee	Egypt	DNA Methyltransferases as Biomarkers for HCV Related Hepatocellular Carcinoma
21	10/3 (Fri)	13:30-14:00	Liver Transplantation-Experimental/ Viral Hepatitis-Clinical	10079	Shatrughna	Nagrik	India	Establishment of a Reproducible Rat Model for Orthotopic Liver Transplantation to Study Post Transplant Immunomodulation and Regeneration
				10062	Ashish	Dhote	India	Hepatic Neuro Axis Crosstalk after Liver Transplantation: Neuroinflammatory Consequences and Pharmacological Neuroprotection in a Rodent Model
				10134	Ming-Ling	Chang	Taiwan	Paradoxical Association between Steatotic Liver Disease and Favorable Hepatic Outcomes in HCV Patients with SVRs
				10029	Pravinkumar Pyarelal	Rejliwal	India	A Pilot Study on Hepatitis B Core Related Antigen (HBcrAg) as a Novel Marker for Monitoring Antiviral Therapy in Chronic Hepatitis B Patients
				10049	Monirujjaman	Biswas	India	Acute Viral Hepatitis in Hospitalized Children: Clinico-Biochemical, Ultrasonographic and Etiological Findings from North India
22	10/3 (Fri)	13:00-13:30	Viral Hepatitis-Clinical	10053	Monirujjaman	Biswas	India	Dual Burden of Infections: Seroprevalence of Acute Viral Hepatitis among Dengue Patients in Northern India
				10050	Monirujjaman	Biswas	India	Clinicoepidemiology and HCV Core Antigen Assay Diagnosis of Hepatitis C: Findings from a Tertiary Care Hospital of North India
				10052	Monirujjaman	Biswas	India	Clinical Profile and Outcomes of Hepatitis A Virus Associated with Severe Acute Liver Injury in Adults: A Case Study of Delhi, India
				10222	Evannelson E P	Wardhana	Indonesia	Hepatocellular Risk Outcomes of Long-term Treatment of Chronic HBV Infection: Network Meta-analysis
				10144	Laode	Kardin	Indonesia	Co-occurrence Hepatic Steatosis and Hepatitis B Virus, Hepatic Steatosis and Hepatitis C Virus at a Tertiary Referral Hospital in Indonesia
23	10/3 (Fri)	13:30-14:00	Liver Fibrosis-Clinical/ MASLD-Clinical	10041	Masafumi	Oyama	Japan	Creatinine-to-cystatin-C Ratios Predict Liver Fibrosis in Patients with Metabolism-associated Steatotic Liver Disease for Reducing Risk of Liver-related Death
				10043	Dae Won	Jun	Korea	Allyl Nonanoate: A Bile Metabolite and Potential Biomarker for Hepatic Fibrosis in MASLD
				10073	Minjeong	Kang	Korea	Pathophysiological Mechanisms Linking MASLD and NCDs and Their Association with Mortality
				10087	Sonoko	Kondo	Japan	Pediatric Nonalcoholic Steatohepatitis in a Patient with Heterozygous Familial Hypobetalipoproteinemia
				10231	Qi	Feng	United Kingdom	Unveiling the True Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a UK Nationwide Cohort
24	10/3 (Fri)	13:00-13:30	Liver Fibrosis-Experimental/ Other Liver Disease-Clinical	10125	Rifaldy	Fajar	Indonesia	Deep Learning-Based Inference of Monocyte-Stromal Crosstalk Predicts Fibrosis-Linked Lower Urinary Tract Dysfunction in Males
				10022	T.	Nakatani	Japan	Beneficial Effects of Milk-Derived Extracellular Vesicles on Liver Fibrosis Progression by Restoring Intestinal Barrier Integrity
				10076	Ji Hoon	Kim	Korea	miR-4449 Modulates the Progression of MASH-induced Fibrosis by Regulating the Merlin-TAZ Pathways
				10157	Masashi	Aiba	Japan	Usefulness of the Stroop Test to Predict Decompensation Events in Patients with Cirrhosis: A Prospective Cohort Study
				10227	Muhammad Bilal	Saifulhaq	Indonesia	Role of Interleukin-6 as Risk Factor of Hepatic Encephalopathy Incidence Compared to Amonia in Liver Cirrhosis Patient
25	10/3 (Fri)	13:30-14:00	Liver Tumor-Clinical/ Liver Tumor-Experimental/ MASLD-Clinical	10108	Dong Yeup	Lee	Korea	PNPLA3 I148M is not Associated with HCC Risk but Correlates with Tumor Differentiation in MASLD Patients
				10129	Mohamed	Abdel-Samiee	Egypt	Latent Transforming Growth Factor-Beta Binding Protein 1 as A Molecular Diagnostic marker for Hepatocellular Carcinoma
				10051	Yoshihiro	Kamada	Japan	Steatotic Liver Disease: An Important Upstream Risk Factor for the Development of Metabolic Syndrome-related Diseases
				10075	Taeho	Kwak	Korea	Short Term and Long Term Regression of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in Older Adults
				10176	Saki	Muronaga	Japan	Establishment of a Mouse Model of Liver Tumorigenesis with Concurrent Steatotic Liver Disease
26	10/3 (Fri)	13:00-13:30	Liver Tumor-Experimental/ MASLD-Clinical	10098	Talia Yi Hui	Chan	Singapore	The Utility of Non-invasive Imaging Modalities for Diagnosing Cirrhosis in Metabolic-dysfunction Associated Steatotic Liver Disease: A Systematic Review
				10017	Karen Cheuk-Ying	Ho	Hong Kong	Prognostic Significance of Bioelectrical Impedance Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
				10032	Xinrui	Jin	Hong Kong	Impact of Hypothyroidism on Liver-related Events among People with Metabolic Dysfunction-associated Steatotic Liver Disease
				10003	Takumi	Kawaguchi	Japan	Association Between Sitting Time and Frailty in Patients with MASLD: A Survey Using the Global Physical Activity Questionnaire (GPAQ)
				10044	Dae Won	Jun	Korea	Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis
27	10/3 (Fri)	13:30-14:00	MASLD-Clinical	10045	Dae Won	Jun	Korea	Cost-effectiveness Analysis of MASLD Screening Using FIB-4 Based Two-step Algorithm in the Medical Check-up
				10084	Yusuke	Johira	Japan	Changes in ALT Levels Following Tirzepatide Initiation in Patients with MASLD
				10104	Jasmin	Lim	Singapore	Uncovering Patient Awareness of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Singapore: Risk Factors, Complications and Management Strategies
				10137	Sunyoung	Lee	Korea	Differences in the Prevalence of NAFLD, MAFLD, and MASLD According to Changes in the Nomenclature in a Health Checkup Using MRI Derived Proton Density Fat Fraction
				10186	Nanoha	Maeda	Japan	Gene Expression Analysis of Immune Rejection in a Mouse Liver Transplantation Model
28	10/3 (Fri)	13:00-13:30	Liver Transplantation-Experimental/ MASLD-Clinical	10142	Yayoi	Yoshinaga	Japan	The Association between Metabolic Abnormalities and the Development of Fatty Liver: A Cohort Study Using a Large Scale Health Check-up Database in Japan
				10155	Premasish	Kar	India	Prevalence of Risk Factors for Non Alcoholic Fatty Liver Disease in Cryptogenic Cirrhosis: A Case Control Study
				10165	Darren J. H.	Tan	Singapore	Changing Trends and Survival Outcomes in MASLD-related Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Analysis
				10170	Taang	Arai	Japan	Incretin-Based Therapies for MASLD with Type 2 Diabetes: Results from Two Prospective Studies
				10175	Mengmeng	Wang	Singapore	The Mechanism of BGB324 and the Effect of AXL Family Inhibitors in MAFLD
29	10/3 (Fri)	13:30-14:00	MASLD-Experimental	10178	Nanoka	Nishida	Japan	Strain-Dependent Susceptibility to Diet-Induced Fatty Liver Disease in Mice
				10187	Mana	Hanasaki	Japan	Effect of the Emulsifier Polysorbate 80 on a Diet-Induced MASLD Mouse Model
				10192	Jung Hoon	Cha	Korea	PNPLA3 I148M GG Variant Promotes Immune Cell Infiltration and is Linked to Metabolic Dysfunction-associated Steatotic Liver Disease Progression
				10219	Y. C.	Hsieh	Taiwan	Hepatocyte-specific (pro)renin Receptor Knockout Attenuated Diet-induced Steatosis in Mice with Improved Insulin Resistance and Metabolic Rates
				10016	Rong	Liu	China	RNA Binding Protein TIA1 Protects Hepatic Lipid Homeostasis and Prevents Fibrotic Nonalcoholic Steatohepatitis through Stress Granule Assembly
30	10/3 (Fri)	13:00-13:30	MASLD-Experimental	10042	Sung Woo	Cho	Korea	Nintedanib Alleviates Metabolic Dysfunction-Associated Steatohepatitis by Suppressing THBS1 Expression in Activated Fibroblasts
				10100	Hyun Ae	Woo	Korea	Mitochondrial ROS Accumulation as a Key Pathogenic Driver in MASLD: Impact of Disrupted Mitochondrial Protein Processing of Antioxidant Enzymes
				10106	Hsin-Hua	Lai	Taiwan	Intestinal Epithelial Peroxisome Proliferator-activated Receptor Gamma; Deficiency Deteriorates Insulin Resistance in Mice with Metabolic Dysfunction-associated Steatohepatitis
				10115	Kei	Minowa	Japan	Maintenance of Mitochondria-driven Oxysterol Metabolism is a Key to Early MASLD Prevention
				10113	Ainura Z	Kutmanova	Kyrgyz	Evaluation of Non-Invasive Fibrosis Markers in HBV-Infected Pregnant Women from the Kyrgyz Republic
31	10/3 (Fri)	13:30-14:00	Liver Fibrosis-Clinical/ Other Liver Disease-Clinical	10039	Vu Van	Khien	Viet Nam	Wilson's Disease in Adults in Vietnam from 2012-2022
				10031	Ngan Thanh Quynh	Le	Viet Nam	Sanger Sequencing in the Diagnosis of Rare Liver Diseases in Southern Vietnam
				10074	Naoki	Shikano	Japan	A Case of PFIC Type7, Demonstrating the Utility of whole Exome Sequencing
				10152	Shinji	Unome	Japan	Frailty is an Independent Predictor of Mortality in Patients with Chronic Liver Disease: A Multicenter Retrospective Cohort Study
				10048	Satoru	Kakizaki	Japan	Evaluation of the Efficacy of Lusutrombopag in Chronic Liver Disease: Impact of Liver Disease Etiology and Pretreatment Platelet Count
32	10/3 (Fri)	13:00-13:30	Other Liver Disease-Clinical	10136	Madiyar	Nagasbekov	Kazakhstan	Integrated Surgical Approach for Hepatic Cystic Echinococcosis: Experience from the Syzganov National Scientific Center of Surgery
				10220	Andi	Makkasau	Indonesia	Integrated Liver Care in Indonesia: A Model Study of Collaboration in the Management of Chronic Liver Disease in Communities
				10201	Hironao	Okubo	Japan	Impact of Partial Splenic Embolization on Pancreatic Congestion with Portal Hypertension
				10033	Harshita	Dubey	India	Evaluation of Chemotherapy-associated Fatty Liver Disease in Epithelial Ovarian Cancer: The Clinical Significance
				10035	Manabu	Hayashi	Japan	Comparison of Noninvasive Test for Histological Cirrhosis in Primary Biliary Cholangitis
33	10/3 (Fri)	13:30-14:00	Liver Fibrosis-Clinical/ Other Liver Disease-Clinical	10226	Resha Dermawansyah	Rusman	Indonesia	Body Mass Index as a Predictor of Liver Fibrosis and Steatosis Grades in Patients with Chronic Liver Disease
				10193	Yohannes Christian	Silalahi	Indonesia	Dengue-Induced Coagulopathy Presenting with Hemorrhagic and Ischemic Stroke: A Rare but Life-Threatening Complication
				10135	Rafael	Romero-Castro	Spain	Endoscopic Ultrasound (EUS)-guided Portal Pressure Gradient Measurement Assessment of Acute Hemodynamic Response to Intravenous Propranolol
				10132	Abdelaziz	Farag	Egypt	The Role of Serum Kallistatin Level in Comparison to Other Non-Invasive Panels for Evaluating Portal Hypertension in Egyptian Cirrhotic Patients
				10094	Akimitsu	Meno	Japan	Prognostic Value of Circulating cfDNA in Patients with Unresectable HCC Receiving Atezolizumab and Bevacizumab
34	10/3 (Fri)	13:00-13:30	Liver Tumor-Clinical	10195	Naoto	Kose	Japan	A Rare Case of Hepatogastric Fistula Induced by Radiofrequency Ablation Combined with Atezolizumab plus Bevacizumab in the Treatment of Hepatocellular Carcinoma
				10110	Junki	Yamashita	Japan	High Proximity of Treg-CD4T Cell Interactions in Spatial Omics Analysis Regulating Cancer Progression in Patients with Hepatocellular Carcinoma
				10117	Michihiko	Kawahara	Japan	A Case of Immune-related Adverse Event Arthritis During Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma
				10172	Mikita	Oi	Japan	Pre-treatment GLIM-defined Malnutrition Predicts Poor Prognosis in Patients with Unresectable Hepatocellular Carcinoma Undergoing Systemic Therapy